Dr Phillip Chad Hawk, PHARMD | |
4197 Crosshaven Dr, Cahaba Heights, AL 35243-5231 | |
(205) 967-4951 | |
Not Available |
Full Name | Dr Phillip Chad Hawk |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 4197 Crosshaven Dr, Cahaba Heights, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720067721 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 15038 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Phillip Chad Hawk, PHARMD 2101 Montreat Pkwy, Apt D, Vestavia Hills, AL 35216-3994 Ph: () - | Dr Phillip Chad Hawk, PHARMD 4197 Crosshaven Dr, Cahaba Heights, AL 35243-5231 Ph: (205) 967-4951 |
News Archive
No, you can't. That's what federal officials told Idaho regulators and the state's governor late Thursday regarding the state's plan to allow insurers to sell health plans that fall short of the Affordable Care Act's requirements.
CareFirst BlueCross BlueShield, the largest health care insurer in the Mid-Atlantic region of the USA, has adopted a policy stating that measurement of exhaled nitric oxide (eNO) is considered medically necessary in the management of asthma patients.
Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
› Verified 4 days ago